Arbutus Biopharma Corporation Is A Clinical Stage Biopharmaceutical Company Based In Warminsterpennsylvaniawith Significant Operations In Burnabybritish Columbiafounded In 2015 Through The Merger Of Tekmira Pharmaceuticals And Oncore Biopharmathe Company Specializes In Developing Novel Therapeutics For Infectious Diseasesparticularly Focusing On Hepatitis B Virushbvthe Company Is Advancing A Pipeline Of Product Candidates Aimed At Treating Chronic Hbv Infectionkey Candidates Include Ab 729A Capsid Assembly Inhibitorimdusiranan Rnai Therapeutic In Clinical Trialsand Ab 101An Oral Pd L1 Inhibitor Designed To Enhance The Immune Response Against Hbvarbutus Biopharma Employs Lipid Nanoparticle Delivery Technologylicensed From Alnylam Pharmaceuticalsto Support Its Drug Development Efforts Arbutus Biopharma Collaborates With Various Partnersincluding Genevant Sciences And Gritstone Oncologyto Enhance Its Capabilities In Drug Developmentthe Company S Mission Is To Address Unmet Medical Needs And Improve Treatment Outcomes For Patients With Chronic Hbv Infection
